Trovagene Inc (TROV) 8.58 $TROV
Interesting TROV Put And Call Options For June 19th
StockOptionsChannel.com - Wed Apr 22, 10:23AM CDT
Investors in TrovaGene Inc saw new options begin trading this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TROV options chain for the new June 19th contracts and identified one put...
TROV: 8.58 (-0.27)
TrovaGene (TROV) Strong On High Relative Volume Today
at The Street - Tue Apr 21, 9:06AM CDT
Trade-Ideas LLC identified TrovaGene (TROV) as a strong on high relative volume candidate
TROV: 8.58 (-0.27)
TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:08PM CDT
Shares of TrovaGene Inc. (TROV) surged 20.14% to close at $8.53 on Apr 17, after the company reported favorable clinical data for its Precision Cancer Monitoring (PCM) technology.
TROV: 8.58 (-0.27), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)
Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research
PR Newswire - Mon Apr 20, 7:35AM CDT
In the search for neuroscience drug discovery treatments, Alzheimer's disease and specifically autism drug candidates, a few viable therapeutic approaches have come from research on neurological conditions such as fragile X syndrome. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), CytRx Corporation (NASDAQ: CYTR), Trovagene, Inc., (NASDAQ: TROV), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Abbot Laboratories (NYSE: ABT) & Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).
ABT: 48.35 (+1.23), LXRX: 1.06 (-0.01), TROV: 8.58 (-0.27), CYTR: 5.21 (-0.06), BMY: 66.60 (-0.21), ARNA: 4.47 (+0.01)
Poster Presentations at 2015 AACR Annual Meeting to Highlight Clinical Utilities and Advantages of Trovagene's ctDNA Precision Cancer Monitoring Platform
PR Newswire - Mon Apr 20, 7:00AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that clinical and analytical data for the Company's Precision Cancer MonitoringSM platform will be presented at the American Association for Cancer Research Annual Meeting in Philadelphia. The data will be presented during the Circulating Free DNA Poster Session from 8 a.m. to noon EDT on April 22. Clinical study results include data for quantitatively monitoring KRAS mutations in pancreatic cancer patients and monitoring for minimal residual disease in metastatic colorectal cancer patients in the adjuvant (post-surgical) setting using liquid biopsy. Analytical results will be presented by the Company, which will include sensitivity data for its CLIA-available assays and the potential advantages of using urine samples to monitor cancer.
TROV: 8.58 (-0.27)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 11:45AM CDT
SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), TROV: 8.58 (-0.27), CHKE: 22.82 (-0.17), XPLR: 6.14 (-0.04), CHOP: 3.67 (-0.26), IPDN: 3.02 (+0.04), GNMK: 10.51 (-0.22), XBIT: 27.55 (+0.18), GBSN: 4.98 (+1.44), NOW: 77.72 (+0.22), CE: 65.75 (-0.19), AMD: 2.28 (-0.07), CYTR: 5.21 (-0.06), TCPI: 3.85 (-0.13), PRO: 23.09 (-0.20), VIMC: 13.42 (+1.31), ATHX: 1.34 (+0.01), DSCO: 1.25 (unch), AWX: 3.65 (-0.02)
Trovagene's urine-based cancer monitoring platform beats biopsies; Shares jump 24%
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 11:31AM CDT
TROV: 8.58 (-0.27)
Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients
PR Newswire - Fri Apr 17, 9:30AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that clinical data presented at the 2015 European Lung Cancer Conference (ELCC) demonstrate that its urine-based Precision Cancer Monitoringâ" (PCM) platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. The abstract, titled Detection of EGFR T790M Mutation in Urinary Circulating Tumor DNA from Metastatic Non-Small Cell Lung Cancer Patients, was presented today by Hatim Husain, M.D., University of California, San Diego Moores Cancer Center during the ESMO-IASLC Best Abstracts session in Geneva, Switzerland.
TROV: 8.58 (-0.27)
InsiderInsights.com Daily Round Up 4/6/15: TROV, MRD, VBFC, IHRT
InsiderInsights - at Seeking Alpha - Tue Apr 07, 7:48AM CDT
ARCW: 7.06 (-0.57), TROV: 8.58 (-0.27), FB: 84.63 (+1.01), GIII: 116.32 (-1.15), MRD: 19.19 (+0.06), ABDC: 13.70 (-0.19), MFRM: 63.45 (-0.24), DSW: 36.68 (+0.08), JLL: 164.33 (+1.11), VBFC: 19.86 (-0.12), WIW: 11.45 (unch), AYN: 14.05 (-0.01), COST: 146.98 (-0.36), BLMN: 22.70 (unch), WIA: 11.60 (-0.04), CRM: 67.71 (+0.33), KPTI: 32.24 (-0.60)
New commercial chief at Trovagene
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 11:14AM CDT
TROV: 8.58 (-0.27)
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer
PR Newswire - Wed Mar 18, 7:31AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Matthew L. Posard has joined the Company as executive vice president & chief commercial officer. Mr. Posard has more than 20 years of experience identifying, directing and successfully commercializing innovative technologies in the molecular diagnostic and life science fields. Most recently, he led the new and emerging market opportunities business at Illumina, Inc. (NASDAQ: ILMN).
HALO: 16.03 (+0.15), TROV: 8.58 (-0.27), ILMN: 190.04 (-9.27)
TrovaGene (TROV) Enters Overbought Territory
Interesting TROV Put And Call Options For June 19th
StockOptionsChannel.com - Wed Apr 22, 10:23AM CDT
Investors in TrovaGene Inc saw new options begin trading this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TROV options chain for the new June 19th contracts and identified one put...
TROV: 8.58 (-0.27)
TrovaGene (TROV) Strong On High Relative Volume Today
at The Street - Tue Apr 21, 9:06AM CDT
Trade-Ideas LLC identified TrovaGene (TROV) as a strong on high relative volume candidate
TROV: 8.58 (-0.27)
TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:08PM CDT
Shares of TrovaGene Inc. (TROV) surged 20.14% to close at $8.53 on Apr 17, after the company reported favorable clinical data for its Precision Cancer Monitoring (PCM) technology.
TROV: 8.58 (-0.27), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)
Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research
PR Newswire - Mon Apr 20, 7:35AM CDT
In the search for neuroscience drug discovery treatments, Alzheimer's disease and specifically autism drug candidates, a few viable therapeutic approaches have come from research on neurological conditions such as fragile X syndrome. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), CytRx Corporation (NASDAQ: CYTR), Trovagene, Inc., (NASDAQ: TROV), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Abbot Laboratories (NYSE: ABT) & Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).
ABT: 48.35 (+1.23), LXRX: 1.06 (-0.01), TROV: 8.58 (-0.27), CYTR: 5.21 (-0.06), BMY: 66.60 (-0.21), ARNA: 4.47 (+0.01)
Poster Presentations at 2015 AACR Annual Meeting to Highlight Clinical Utilities and Advantages of Trovagene's ctDNA Precision Cancer Monitoring Platform
PR Newswire - Mon Apr 20, 7:00AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that clinical and analytical data for the Company's Precision Cancer MonitoringSM platform will be presented at the American Association for Cancer Research Annual Meeting in Philadelphia. The data will be presented during the Circulating Free DNA Poster Session from 8 a.m. to noon EDT on April 22. Clinical study results include data for quantitatively monitoring KRAS mutations in pancreatic cancer patients and monitoring for minimal residual disease in metastatic colorectal cancer patients in the adjuvant (post-surgical) setting using liquid biopsy. Analytical results will be presented by the Company, which will include sensitivity data for its CLIA-available assays and the potential advantages of using urine samples to monitor cancer.
TROV: 8.58 (-0.27)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 11:45AM CDT
SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), TROV: 8.58 (-0.27), CHKE: 22.82 (-0.17), XPLR: 6.14 (-0.04), CHOP: 3.67 (-0.26), IPDN: 3.02 (+0.04), GNMK: 10.51 (-0.22), XBIT: 27.55 (+0.18), GBSN: 4.98 (+1.44), NOW: 77.72 (+0.22), CE: 65.75 (-0.19), AMD: 2.28 (-0.07), CYTR: 5.21 (-0.06), TCPI: 3.85 (-0.13), PRO: 23.09 (-0.20), VIMC: 13.42 (+1.31), ATHX: 1.34 (+0.01), DSCO: 1.25 (unch), AWX: 3.65 (-0.02)
Trovagene's urine-based cancer monitoring platform beats biopsies; Shares jump 24%
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 11:31AM CDT
TROV: 8.58 (-0.27)
Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients
PR Newswire - Fri Apr 17, 9:30AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that clinical data presented at the 2015 European Lung Cancer Conference (ELCC) demonstrate that its urine-based Precision Cancer Monitoringâ" (PCM) platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. The abstract, titled Detection of EGFR T790M Mutation in Urinary Circulating Tumor DNA from Metastatic Non-Small Cell Lung Cancer Patients, was presented today by Hatim Husain, M.D., University of California, San Diego Moores Cancer Center during the ESMO-IASLC Best Abstracts session in Geneva, Switzerland.
TROV: 8.58 (-0.27)
InsiderInsights.com Daily Round Up 4/6/15: TROV, MRD, VBFC, IHRT
InsiderInsights - at Seeking Alpha - Tue Apr 07, 7:48AM CDT
ARCW: 7.06 (-0.57), TROV: 8.58 (-0.27), FB: 84.63 (+1.01), GIII: 116.32 (-1.15), MRD: 19.19 (+0.06), ABDC: 13.70 (-0.19), MFRM: 63.45 (-0.24), DSW: 36.68 (+0.08), JLL: 164.33 (+1.11), VBFC: 19.86 (-0.12), WIW: 11.45 (unch), AYN: 14.05 (-0.01), COST: 146.98 (-0.36), BLMN: 22.70 (unch), WIA: 11.60 (-0.04), CRM: 67.71 (+0.33), KPTI: 32.24 (-0.60)
New commercial chief at Trovagene
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 11:14AM CDT
TROV: 8.58 (-0.27)
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer
PR Newswire - Wed Mar 18, 7:31AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Matthew L. Posard has joined the Company as executive vice president & chief commercial officer. Mr. Posard has more than 20 years of experience identifying, directing and successfully commercializing innovative technologies in the molecular diagnostic and life science fields. Most recently, he led the new and emerging market opportunities business at Illumina, Inc. (NASDAQ: ILMN).
HALO: 16.03 (+0.15), TROV: 8.58 (-0.27), ILMN: 190.04 (-9.27)
TrovaGene (TROV) Enters Overbought Territory
